Radiopharm Theranostics Limited

RAD

AU0000181851

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 01:57:47 2024-06-19 am EDT			5-day change	1st Jan Change
0.034 ^AUD	+13.33%		+13.33%	-54.05%

Jun. 20	US Radiopharmaceutical Firm to Invest Up to AU$18 Million into Radiopharm Theranostics	MT
May. 08	Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities	MT

Radiopharm Theranostics talks clinical development and Nasdaq listing

February 14, 2023 at 01:01 pm EST

(via NewsDirect)

Radiopharm Theranostics Ltd (ASX:RAD) CEO and managing director Riccardo Canevari tells Proactive the company has begun the initiation process for entry into the Nasdaq stock exchange under the ticker RADX, gaining a second listing in the US capital market. RAD’s recently announced that it has received US FDA Investigational New Drug Application (IND) approval for its αVβ6 Integrin (RAD301) technology. With this approval the company can start a Phase 1 imaging trial in ambulatory patients with pancreatic cancer.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about Radiopharm Theranostics Limited

US Radiopharmaceutical Firm to Invest Up to AU$18 Million into Radiopharm Theranostics	Jun. 19	MT
Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities	May. 08	MT
Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study	Feb. 29	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Radiopharm Theranostics Receives AU$1.9 Million Advance on R&D Tax Rebate	Feb. 20	MT
Radiopharm Secures Investment from US-based Lind Partners; Shares Decline 6%	Feb. 06	MT
Radiopharm Theranostics Raises AU$1.7 Million Via Shortfall Placement	Jan. 23	MT
Radiopharm Theranostics Secures Ethics Approval for Second Lung Cancer Trial Site	Dec. 26	MT
Radiopharm Theranostics to Start Phase One Lung Cancer Therapy Trial	Dec. 25	MT
Radiopharm Theranostics Raises AU$2.1 Million Via Entitlement Offer	Dec. 08	MT
28,046,696 Options of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	Nov. 24	CI
100,000,000 Ordinary Shares of Radiopharm Theranostics Limited are subject to a Lock-Up Agreement Ending on 25-NOV-2023.	Nov. 24	CI
Radiopharm Theranostics Secures AU$5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 4%	Nov. 20	MT
Radiopharm Theranostics Secures US FDA Approval for Phase 1 Pancreatic Cancer Diagnostic Trial	23-10-17	MT
Radiopharm Theranostics Secures Ethics Approval for Lung Cancer Trial; Shares Rise 4%	23-10-08	MT
Radiopharm Theranostics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Radiopharm Theranostics Secures US FDA Guidance for Clinical Trial of Imaging Drug in Brain Metastasis	23-05-29	MT
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer	23-05-09	CI
Radiopharm Theranostics Receives US FDA Orphan Drug Designation for Pancreatic Cancer Medication	23-05-09	MT
Radiopharm Theranostics Receives AU$1.6 Million R&D Tax Refund; Shares Fall 3%	23-03-27	MT
Radiopharm Theranostics, GenesisCare Partner to Develop Novel Radiopharmaceuticals in Australia	23-03-26	MT
Radiopharm Theranostics Limited and GenesisCare to Develop Novel Radiopharmaceuticals	23-03-26	CI
Radiopharm Theranostics Appoints Dr. Ken Herrmann to the Scientific Advisory Board	23-03-03	CI
Radiopharm Theranostics Acquiring Pharma15 for AU$6 Million	23-03-03	MT
Radiopharm Theranostics Limited entered into a binding agreement to acquire Pharma15 Corporation.	23-03-02	CI

Chart Radiopharm Theranostics Limited

Duration

Period

More charts

Company Profile

Radiopharm Theranostics Limited is an Australia-based clinical-stage company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. It has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

Sector

Pharmaceuticals

Calendar

2024-09-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Radiopharm Theranostics Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0227 USD

Average target price

0.334 USD

Spread / Average Target

+1,372.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
RADIOPHARM THERANOSTICS LIMITED	-54.05%	10.38M
ELI LILLY AND COMPANY	+53.95%	796B
NOVO NORDISK A/S	+41.58%	628B
JOHNSON & JOHNSON	-4.61%	358B
MERCK & CO., INC.	+21.36%	331B
ABBVIE INC.	+11.03%	301B
ASTRAZENECA PLC	+17.72%	244B
ROCHE HOLDING AG	+4.46%	228B
NOVARTIS AG	+13.13%	214B
AMGEN INC.	+9.44%	165B

Other Pharmaceuticals

Radiopharm Theranostics Limited

Equities

RAD

AU0000181851

Pharmaceuticals

Radiopharm Theranostics talks clinical development and Nasdaq listing

Contact Details

Latest news about Radiopharm Theranostics Limited

Chart Radiopharm Theranostics Limited

Company Profile

Income Statement Evolution

Ratings for Radiopharm Theranostics Limited

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals